Latest News
CelLBxHealth secures USD65,000 pharmaceutical research contract
14 October 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) reported on Wednesday that it has signed a new Statement of Work (SOW) worth approximately USD65,000 under an existing Master Services Agreement with a US-based pharmaceutical co...
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
14 October 2026 - Biopharmaceutical company Legacy Healthcare announced on Tuesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to CINAINU (LH-8), its investigational cutaneous solution treatment for mod...
Paradigm Therapeutics named finalist for 2026 Prix Galien USA 'Best Start-Up' Award
14 October 2026 - Clinical-stage biopharmaceutical company Paradigm Therapeutics Inc announced on Tuesday that it has been named a finalist for the 2026 Prix Galien USA 'Best Start-Up' Award.This is the second consecutive year that Paradigm...
FDA approves Vantis Vascular's 6F CrossFAST model
14 October 2026 - Medical technology company Vantis Vascular announced on Tuesday that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for a new 6 French (6F) model of its CrossFAST Integrated Microcatheter Advanced De...
Racura Oncology receives approval for RC220 trial to proceed to higher dose
13 October 2026 - Racura Oncology Limited (ASX:RAC), a late clinical-stage biopharmaceutical company, announced on Monday that the Safety Review Committee (SRC) for the Phase 1 HARNESS-1 trial has approved its lead oncology drug, RC220, to proceed to...